Clinical Trial 20963

A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

Disease Site: Myeloid and Monocytic Leukemia

PI: Kuykendall, Andrew

Clinical Trial 22095

A Phase 2 study of Canakinumab in patients with Myelofibrosis

Disease Site: Myeloid and Monocytic Leukemia

PI: Kuykendall, Andrew

Clinical Trial 22071

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

Disease Site: Other

PI: Zager, Jonathan

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Disease Site: Bones and Joints, Rhabdomyosarcoma

PI: Metts, Jonathan

Clinical Trial 20871

A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)

Disease Site: Unknown Sites

PI: Nishihori, Taiga

Clinical Trial 22003

A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog

Disease Site: Prostate

PI: Zhang, Jingsong

Clinical Trial 21997

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Disease Site: Other Skin

PI: Eroglu, Zeynep

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach

PI: Kim, Dae Won

Clinical Trial 22100

Disease Site: Multiple Myeloma

PI: Grajales-Cruz, Ariel

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

Disease Site: Lung

PI: Gray, Jhanelle

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

PI: Gaballa, Sameh

Clinical Trial 21024

A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

Disease Site: Brain and Nervous System

PI: Forsyth, Peter